← All trials
NCT05971602
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2023
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Aug 2, 2023
- Last posted
- Dec 8, 2023
- Enrollment
- 514
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bill and Melinda Gates FoundationLead sponsor
- OtsukaCollaborator
- Global Alliance for TB Drug DevelopmentCollaborator
- Janssen Pharmaceutica NVCollaborator
- Bill and Melinda Gates FoundationStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.